Cancer Chemotherapy Update

Solimando Jr., Dominic A.; Waddell, Aubrey
October 2009
Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858
Academic Journal
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E Lamar Alexander Parkway, Maryville, TN 37804, e - mail: waddfour@charter.net.


Related Articles

  • Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Scholz, M.; Engert, A.; Franklin, J.; Josting, A.; Diehl, V.; Hasenclever, D.; Loeffler, M. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p681 

    Background: Using a parametric carcinogenesis model, we disentangle the superimposing effects of primary and relapse therapies of Hodgkin's disease on secondary neoplasias.Patients and methods: We analyze eight randomized trials of the German Hodgkin's lymphoma study group [5357 individuals, 67...

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386 

    Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or...

  • FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Markova, J.; Kobe, C.; Skopalova, M.; Klaskova, K.; Dedeckova, K.; Plütschow, A.; Eich, H. T.; Dietlein, M.; Engert, A.; Kozak, T. // Annals of Oncology;Jul2009, Vol. 20 Issue 7, p1270 

    Background: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,...

  • A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Niitsu, Nozomi; Tamaru, Jun-ichi; Yoshino, Tadashi; Nakamura, Naoya; Nakamura, Shigeo; Ohshima, Kohichi; Nakamine, Hirokazu; Okamoto, Masataka // Annals of Hematology;Feb2011, Vol. 90 Issue 2, p185 

    In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The...

  • A Preliminary Study on the Occurrence of Cytostatic Drugs in Hospital Effluents in Beijing, China. Jie Yin; Bing Shao; Jing Zhang; Keji Li // Bulletin of Environmental Contamination & Toxicology;Jan2010, Vol. 84 Issue 1, p39 

    Cytostatic drugs are used in cancer therapy. They can enter hospital wastewater due to excretion by patients undergoing chemotherapy. Little attention has been paid to these drugs in China even though their usage is high. The effluents of 21 hospitals of different size in Beijing, China, were...

  • Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma. Barrington, S. F.; MacKewn, J. E.; Schleyer, P.; Marsden, P. K.; Mikhaeel, N. G.; Qian, W.; Mouncey, P.; Patrick, P.; Popova, B.; Johnson, P.; Radford, J.; O'Doherty, M. J. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p739 

    Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose–positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are...

  • Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. Hughes, Caren L.; Yorio, Jeffrey T.; Kovitz, Craig; Oki, Yasuhiro // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p567 

    Introduction Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy causes paresthesias and weakness, which can make the treatment of...

  • Antineoplastics.  // Reactions Weekly;10/21/2006, Issue 1124, p6 

    The article presents the case of a 31-year-old man who developed telangiectasia after receiving antineoplastic therapy with doxorubicin, bleomycin, vinblastine and dacarbazine for Hodgkin's disease. It references a study by M. Rodríguez-Martín et al, published in the September 2006 issue...

  • cyclophosphamide. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p208 

    A definition of the term "cyclophosphamide" is presented. It refers to an anticancer drug used in the treatment of Hodgkin's disease and leukaemia. Cyclophosphamide may also be used as an immunosuppressant and for treating connective tissue diseases.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics